Rubbo, Pierre-Alain
Soupé-Gilbert, Marie-Estelle
Golongba, Davy Martial
Mbombo, Florent
Girault, Dominique
Nakouné, Emmanuel
Lombart, Jean-Pierre
Breurec, Sébastien
Goarant, Cyrille
Funding for this research was provided by:
Institut Pasteur International Network (ACIP grant 2012-A22)
Institut Pasteur de Bangui
Article History
Received: 28 February 2018
Accepted: 1 August 2018
First Online: 7 August 2018
Ethics approval and consent to participate
: The Central African Republic scientific committee for validation of protocols, results and studies approved the study and allowed utilization and exportation of serum samples stored in Institut Pasteur de Bangui for the ACIP22/2012 relating to the Leptospirosis diagnostic study.The surveillance program for the YFV was approved by the Ministry of Health in Central African Republic and it was subject to mandatory declaration (yellow fever and other haemorrhagic fevers). In this context, patient consent was not necessary. The references of the approval and validation notifications from the Central African Republic scientific committee are 04/UB/FACSS/CSCVPER/17 and 05/UB/FACSS/CSCVPER/17.
: Not applicable.
: Pierre-Alain RUBBO is the Founding Chief Executive Officer, and one of the shareholders, of the Omunis start-up company. Omunis did not provide any support in the form of salaries for authors, and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.